You are here

  • Home
  • Archive
  • Volume 19, Issue 2
  • Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCAs) were stopped, versus continuation with FDCAs

Article metrics

Article menu
Download PDFPDF
Abstracts
Drug information (i. Anti-infectives, ii. cytostatics, iii. others)
Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCAs) were stopped, versus continuation with FDCAs

 

Online download statistics by month:

Online download statistics by month: March 2012 to March 2024

AbstractFullPdf
Mar 2012600
Apr 2012702
May 2012611
Jun 2012504
Jul 2012304
Aug 2012600
Sep 20121200
Oct 20121701
Nov 20121101
Dec 2012700
Jan 20131100
Feb 2013100
Mar 20131600
Apr 2013500
May 2013900
Jul 2013100
Sep 2013300
Oct 2013300
Nov 2013200
Dec 2013200
Feb 2014100
Mar 2014100
May 2014100
Jun 2014500
Jul 2014600
Aug 2014700
Oct 2014600
Nov 2014500
Dec 2014200
Jan 2015300
Feb 2015300
Apr 2015400
May 2015300
Jul 2015300
Sep 2015500
Oct 2015100
Nov 20151100
Jan 2016100
Feb 2016100
May 2016100
Jun 2016200
Jul 2016500
Aug 2016800
Sep 2016500
Oct 2016200
Nov 2016600
Dec 2016200
Jan 2017300
Feb 2017300
Mar 2017400
Apr 2017300
May 2017300
Jun 2017200
Jul 2017200
Aug 2017200
Sep 2017200
Oct 2017400
Nov 2017400
Dec 20171000
Jan 2018600
Feb 2018600
Mar 2018800
Apr 20181400
May 2018600
Jun 2018600
Jul 2018600
Aug 2018600
Sep 2018400
Nov 2018400
Dec 2018900
Jan 2019200
Feb 20191000
Mar 2019600
Apr 2019200
May 2019200
Jul 2019200
Sep 2019400
Oct 2019400
Dec 2019200
Jan 2020600
Feb 2020200
Apr 2020400
Jun 2020400
Jul 2020200
Aug 20201002
Sep 2020400
Oct 2020600
Nov 2020200
Dec 2020400
Jan 2021800
Feb 2021400
Apr 2021200
Jun 2021200
Oct 2021400
Nov 20211100
Dec 20211100
Jan 20221300
Feb 2022900
Mar 2022600
May 2022400
Jun 20221000
Jul 2022400
Aug 2022400
Nov 2022600
Dec 20221000
Jan 2023200
Mar 2023200
Apr 2023400
May 2023600
Jun 2023400
Jul 2023200
Sep 2023400
Nov 2023400
Dec 2023200
Mar 2024600
Total572115